ASP 6294

Drug Profile

ASP 6294

Alternative Names: ASP6294

Latest Information Update: 19 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Class Antibodies; Urologics
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Interstitial cystitis

Most Recent Events

  • 28 Sep 2017 Phase-II clinical trials in Interstitial cystitis in Spain, Hungary, Germany, Latvia, Czech Republic (SC) (EudraCT2016-004138-12) (NCT03282318)
  • 18 Sep 2017 Astellas Pharma plans the SERENITY phase II trial for Interstitial cystitis (NCT03282318)
  • 09 Jan 2017 Astellas Pharma completes a phase-I trial in Interstitial cystitis (In volunteers) in United Kingdom (IV, SC) (NCT02681861)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top